Related Experiment Videos
Three novel mutations in the RET proto-oncogene
V N Kalinin1, F A Amosenko, M A Shabanov
1Research Laboratory, Department for General Surgery, Hamburg University Hospital Eppendorf, Martinistrasse 52, 20251 Hamburg, Germany. kalinin@uke.uni-hamburg.de
Abstract:
Medullary thyroid carcinoma (MTC) occurs as a sporadic tumor or in connection with inherited cancer syndromes of multiple endocrine neoplasia type 2 and familial MTC. Missense RET proto-oncogene mutations and small in-frame deletions are found in most of the cases. In a significant amount of sporadic MTC cases somatic mutation at codon 918 (exon 16), or at codons 609, 611, 618, 620 (exon 10), or codons 630, 634 (exon 11) appear. We report here on three new somatic cell missense mutations of the RET proto-oncogene associated with sporadic MTC. In one tumor mutation at codon 922 TCC(Ser)-->TTC(Phe) in exon 16 was found. In another tumor two mutations at codons 639 GCA(Ala)-->GGA(Gly) and 641 GCT(Ala)-->CGT(Arg) in the exon 11 were observed. Allele-specific PCR followed by sequencing demonstrated the presence of both mutations at the same allele.
Insights
This study identifies novel RET proto-oncogene mutations in sporadic medullary thyroid carcinoma (MTC). These findings contribute to understanding the genetic landscape of MTC and may inform future diagnostic and therapeutic strategies.
Area of Science:
- Oncology
- Genetics
- Endocrinology
Background:
- Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor arising from parafollicular C-cells.
- MTC can be sporadic or associated with inherited syndromes like multiple endocrine neoplasia type 2.
- Activating mutations in the RET proto-oncogene are key drivers in MTC development.
Purpose of the Study:
- To identify and characterize novel somatic mutations in the RET proto-oncogene in sporadic MTC.
- To expand the understanding of the mutational spectrum of RET in MTC.
- To correlate specific RET mutations with sporadic MTC pathogenesis.
Main Methods:
- Somatic cell DNA extraction from MTC tumor tissues.
- Polymerase chain reaction (PCR) amplification of RET proto-oncogene exons.
- DNA sequencing to identify missense mutations and deletions.
Main Results:
- Identification of three new somatic missense mutations in the RET proto-oncogene in sporadic MTC.
- A novel mutation at codon 922 (TCC>TTC) in exon 16.
- Two novel mutations at codons 639 (GCA>GGA) and 641 (GCT>CGT) in exon 11, found on the same allele.
Conclusions:
- The study reports novel RET proto-oncogene mutations associated with sporadic MTC.
- These findings highlight the diverse mutational landscape of RET in MTC.
- Further research is warranted to explore the functional impact and clinical relevance of these newly identified mutations.